Kazuhiko Ikeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuhiko Ikeda has a total of 275 co-authors. Here are the top co-authors by number of shared publications:
Yasuchika Takeishi
Department of Cardiovascular Medicine Fukushima Medical University Fukushima Fukushima Japan
14 shared publicationsKazuei Ogawa
Department of Hematology, School of Medicine, Fukushima Medical University, Fukushima, Japan
11 shared publicationsKeiji Minakawa
Department of Blood Transfusion and Transplantation Immunology, School of Medicine, Fukushima Medical University, Fukushima, Japan
11 shared publications- Yasuchika Takeishi
Department of Cardiovascular Medicine Fukushima Medical University Fukushima Japan
11 shared publications Hideyoshi Noji
Department of Cardiology and Hematology, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan
9 shared publications- Kazuei Ogawa
Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan
9 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Role of Interleukin 34 in Pulmonary Vascular Remodeling Associated With Fibrosing Interstitial Lung Disease
Pulmonary hypertension with fibrosing interstitial lung disease is characterized by progressive pulmonary vascular remodeling and poor prognosis. Although inflammation and macrophage activation contribute to vascular remodeling, upstream mediators remain incompletely defined. Interleukin 34 (IL34), a ligand of colony‐stimulating factor‐1 receptor, regulates macrophage differentiation and recruitment. The objective is to elucidate the role of IL34 in pulmonary vascular remodeling associated with fibrosing interstitial lung disease. We investigated human lung samples, in vitro studies, using a murine model of pulmonary hypertension with fibrosing interstitial lung disease, and smooth muscle cell‐specific IL34‐deficient mice. IL34 expression was increased in the pulmonary arteries of patients with fibrosing interstitial lung disease with pulmonary vascular remodeling. IL34 was upregulated in pulmonary artery smooth muscle cells in a murine model of pulmonary hypertension with fibrosing interstitial lung disease, promoting osteopontin production in macrophages. Smooth muscle cell‐specific IL34 deficiency attenuated right ventricular systolic pressure, right ventricular hypertrophy, vascular remodeling, and perivascular macrophage accumulation in a murine model of pulmonary hypertension with fibrosing interstitial lung disease. Osteopontin from IL34‐induced macrophages promoted pulmonary artery smooth muscle cell proliferation. These findings identify smooth muscle cell‐derived IL34 as a contributor to pulmonary vascular remodeling associated with fibrosing interstitial lung disease.
- 30 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Open AccessRole of Interleukin 34 in Pulmonary Vascular Remodeling Associated With Fibrosing Interstitial Lung Disease
Pulmonary hypertension with fibrosing interstitial lung disease is characterized by progressive pulmonary vascular remodeling and poor prognosis. Although inflammation and macrophage activation contribute to vascular remodeling, upstream mediators remain incompletely defined. Interleukin 34 (IL34), a ligand of colony‐stimulating factor‐1 receptor, regulates macrophage differentiation and recruitment. The objective is to elucidate the role of IL34 in pulmonary vascular remodeling associated with fibrosing interstitial lung disease. We investigated human lung samples, in vitro studies, using a murine model of pulmonary hypertension with fibrosing interstitial lung disease, and smooth muscle cell‐specific IL34‐deficient mice. IL34 expression was increased in the pulmonary arteries of patients with fibrosing interstitial lung disease with pulmonary vascular remodeling. IL34 was upregulated in pulmonary artery smooth muscle cells in a murine model of pulmonary hypertension with fibrosing interstitial lung disease, promoting osteopontin production in macrophages. Smooth muscle cell‐specific IL34 deficiency attenuated right ventricular systolic pressure, right ventricular hypertrophy, vascular remodeling, and perivascular macrophage accumulation in a murine model of pulmonary hypertension with fibrosing interstitial lung disease. Osteopontin from IL34‐induced macrophages promoted pulmonary artery smooth muscle cell proliferation. These findings identify smooth muscle cell‐derived IL34 as a contributor to pulmonary vascular remodeling associated with fibrosing interstitial lung disease.
- 26 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1797-1806
Donor age as a dual‐risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation
Summary: Donor selection in allogeneic haematopoietic stem cell transplantation (allo‐HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual—association donor factors (DADFs)—donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival—using umbilical cord blood (UCB) as a donor‐safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013–2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)‐adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post‐transplant cyclophosphamide (OD‐PTCy‐Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW‐adjusted analyses, allo‐HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse‐free survival (RFS) compared with UCB. In PSM analyses of elderly high‐risk recipients, OD‐PTCy‐Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high‐risk settings.
- 26 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1797-1806
Donor age as a dual‐risk factor for donor safety and recipient survival in allogeneic haematopoietic stem cell transplantation
Summary: Donor selection in allogeneic haematopoietic stem cell transplantation (allo‐HSCT) requires balancing donor safety and recipient survival. We aimed to identify dual—association donor factors (DADFs)—donor characteristics associated with both increased serious adverse events (SAEs) and inferior patient survival—using umbilical cord blood (UCB) as a donor‐safety benchmark. This nationwide retrospective cohort study analysed Japanese registry data (2013–2022) including 22 892 donors and 29 559 recipients. Logistic regression identified donor SAE risk factors, while patient outcomes were evaluated using inverse probability of treatment weighting (IPTW)‐adjusted Cox models with UCB as reference. Propensity score matching (PSM) compared UCB with older donor haploidentical transplantation using post‐transplant cyclophosphamide (OD‐PTCy‐Haplo). Among donors, 93 (0.41%) experienced an SAE. Older donor age and female sex were independent risk factors for SAE. In IPTW‐adjusted analyses, allo‐HSCT from older haploidentical donors was associated with inferior overall survival (OS) and relapse‐free survival (RFS) compared with UCB. In PSM analyses of elderly high‐risk recipients, OD‐PTCy‐Haplo resulted in significantly worse OS and RFS than UCB. Older donor age emerged as a donor characteristic associated with increased donor SAE risk and inferior patient survival, particularly in haploidentical transplantation. UCB may offer a more favourable balance between donor safety and patient outcomes in selected high‐risk settings.
- 13 December 2025
- Published by Elsevier in Experimental Hematology
- Vol. 155, 105350
Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms
- 13 December 2025
- Published by Elsevier in Experimental Hematology
- Vol. 155, 105350
Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms
- 22 September 2025
- Published by Wiley in Transfusion
- Vol. 65 (11) , 2024-2033
Rapid thawing of fresh frozen plasma with a 45°C dry tempering system maintains critical coagulation activities
Background: The ability to rapidly transfuse similar volumes of fresh frozen plasma (FFP) and packed red blood cells can reduce mortality in patients with critical bleeding. This is a compelling reason to thaw FFP quickly in real‐world clinical practice. A new dry tempering system thaws FFP between two aluminum panels that are maintained at a specific temperature. The FP‐2000 (for two bags) and FP‐4000 (for four bags) thaw FFP at 37°C (Dry NORMAL mode) and 45°C (Dry EXPRESS mode). Study Design and Methods: We compared FFP thawed in a conventional water bath with FFP thawed by dry tempering at 37°C and 45°C, with particular attention to thawing speed, subsequent coagulation factor activity, and evidence of precipitation or denaturation of proteins. Results: Dry tempering can thaw FFP without bag damage or risks associated with contaminated water. Dry EXPRESS mode at 45°C could thaw FFP as fast as a water bath and had significantly shorter thawing durations than Dry NORMAL mode at 37°C for 240 mL and 480 mL bags. Moreover, both Dry EXPRESS mode and Dry NORMAL mode maintained coagulation factor activities in thawed FFP, with no evidence of protein precipitation or denaturation. Discussion: Dry tempering is useful for thawing FFP in real‐world clinical situations. In contrast to open water baths, dry tempering systems could be incorporated into ambulance and emergency response vehicles responding to traumatic bleeding events. Uniquely, the new dry tempering system at 45°C could save precious minutes in a massive transfusion protocol while preserving FFP coagulation activity.
- 22 September 2025
- Published by Wiley in Transfusion
- Vol. 65 (11) , 2024-2033
Rapid thawing of fresh frozen plasma with a 45°C dry tempering system maintains critical coagulation activities
Background: The ability to rapidly transfuse similar volumes of fresh frozen plasma (FFP) and packed red blood cells can reduce mortality in patients with critical bleeding. This is a compelling reason to thaw FFP quickly in real‐world clinical practice. A new dry tempering system thaws FFP between two aluminum panels that are maintained at a specific temperature. The FP‐2000 (for two bags) and FP‐4000 (for four bags) thaw FFP at 37°C (Dry NORMAL mode) and 45°C (Dry EXPRESS mode). Study Design and Methods: We compared FFP thawed in a conventional water bath with FFP thawed by dry tempering at 37°C and 45°C, with particular attention to thawing speed, subsequent coagulation factor activity, and evidence of precipitation or denaturation of proteins. Results: Dry tempering can thaw FFP without bag damage or risks associated with contaminated water. Dry EXPRESS mode at 45°C could thaw FFP as fast as a water bath and had significantly shorter thawing durations than Dry NORMAL mode at 37°C for 240 mL and 480 mL bags. Moreover, both Dry EXPRESS mode and Dry NORMAL mode maintained coagulation factor activities in thawed FFP, with no evidence of protein precipitation or denaturation. Discussion: Dry tempering is useful for thawing FFP in real‐world clinical situations. In contrast to open water baths, dry tempering systems could be incorporated into ambulance and emergency response vehicles responding to traumatic bleeding events. Uniquely, the new dry tempering system at 45°C could save precious minutes in a massive transfusion protocol while preserving FFP coagulation activity.
- Open Access
Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation
Chimerism analysis after allogeneic hematopoietic stem cell transplantation serves to confirm engraftment, indicate relapse of hematologic malignancy, and attribute graft failure to either immune rejection or poor graft function. Short tandem repeat PCR (STR-PCR) is the prevailing method, followed by quantitative real-time PCR (qPCR), with detection limits of 1–5% and 0.1%, respectively. Chimerism assays using digital PCR or next-generation sequencing, both of which are more sensitive than STR-PCR, are increasingly used. Stable mixed chimerism is usually not associated with poor outcomes in non-malignant diseases, but recipient chimerism may foretell relapse of hematologic malignancies, so higher detection sensitivity may be beneficial in such cases. Thus, the need for and the type of intervention, e.g., immunosuppression regimen, donor lymphocyte infusion, and/or salvage second transplantation, should be guided by donor chimerism in the context of the feature and/or residual malignant cells of the disease to be treated.
Open AccessProspects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation
Chimerism analysis after allogeneic hematopoietic stem cell transplantation serves to confirm engraftment, indicate relapse of hematologic malignancy, and attribute graft failure to either immune rejection or poor graft function. Short tandem repeat PCR (STR-PCR) is the prevailing method, followed by quantitative real-time PCR (qPCR), with detection limits of 1–5% and 0.1%, respectively. Chimerism assays using digital PCR or next-generation sequencing, both of which are more sensitive than STR-PCR, are increasingly used. Stable mixed chimerism is usually not associated with poor outcomes in non-malignant diseases, but recipient chimerism may foretell relapse of hematologic malignancies, so higher detection sensitivity may be beneficial in such cases. Thus, the need for and the type of intervention, e.g., immunosuppression regimen, donor lymphocyte infusion, and/or salvage second transplantation, should be guided by donor chimerism in the context of the feature and/or residual malignant cells of the disease to be treated.
- 28 July 2023
- Published by Elsevier in The Lancet Haematology
- Vol. 10 (9) , e699-e700
FIT for surgery: fractures, iron, and tranexamic acid
- 28 July 2023
- Published by Elsevier in The Lancet Haematology
- Vol. 10 (9) , e699-e700
FIT for surgery: fractures, iron, and tranexamic acid
- Open Access
Impaired Repopulating Ability of Uhrf2−/− Hematopoietic Progenitor Cells in Mice
UHRF proteins catalyze the ubiquitination of target proteins and are involved in regulating gene expression. Some studies reported a reduced expression of UHRF2 in acute leukemia cells, but the role of UHRF2 in hematopoiesis remains unknown. Here, we generated Uhrf2−/− mice to clarify the role of UHRF2 deletion in hematopoiesis. Compared to Uhrf2+/+ mice, Uhrf2−/− mice showed no differences in complete blood counts, as well as bone marrow (BM) findings and spleen weights. Proportions of cells in progenitor fractions in BM were comparable between Uhrf2+/+ mice and Uhrf2−/− mice. However, in competitive repopulation assays with BM transplants (BMT), the proportions of Uhrf2−/− cells were decreased relative to Uhrf2+/+ cells in all lineages. After the second BMT, Uhrf2−/− neutrophils were few, while 20–30% of Uhrf2−/− T cells and B cells were still detected. RNA sequencing showed downregulation of some genes associated with stem-cell function in Uhrf2−/− hematopoietic stem/progenitor cells (HSPCs). Interestingly, trimethylated histone H3 lysine 9 was increased in Uhrf2−/− HSPCs in a cleavage under targets and tagmentation assay. While UHRF2 deletion did not cause hematologic malignancy or confer a growth advantage of HSPCs, our results suggest that UHRF2 may play a role in the regulation of hematopoiesis.
Open AccessImpaired Repopulating Ability of Uhrf2−/− Hematopoietic Progenitor Cells in Mice
UHRF proteins catalyze the ubiquitination of target proteins and are involved in regulating gene expression. Some studies reported a reduced expression of UHRF2 in acute leukemia cells, but the role of UHRF2 in hematopoiesis remains unknown. Here, we generated Uhrf2−/− mice to clarify the role of UHRF2 deletion in hematopoiesis. Compared to Uhrf2+/+ mice, Uhrf2−/− mice showed no differences in complete blood counts, as well as bone marrow (BM) findings and spleen weights. Proportions of cells in progenitor fractions in BM were comparable between Uhrf2+/+ mice and Uhrf2−/− mice. However, in competitive repopulation assays with BM transplants (BMT), the proportions of Uhrf2−/− cells were decreased relative to Uhrf2+/+ cells in all lineages. After the second BMT, Uhrf2−/− neutrophils were few, while 20–30% of Uhrf2−/− T cells and B cells were still detected. RNA sequencing showed downregulation of some genes associated with stem-cell function in Uhrf2−/− hematopoietic stem/progenitor cells (HSPCs). Interestingly, trimethylated histone H3 lysine 9 was increased in Uhrf2−/− HSPCs in a cleavage under targets and tagmentation assay. While UHRF2 deletion did not cause hematologic malignancy or confer a growth advantage of HSPCs, our results suggest that UHRF2 may play a role in the regulation of hematopoiesis.
- 26 January 2023
- Published by Elsevier in The Lancet
- Vol. 401 (10373) , 248-249
Gaining MOMENTUM against anaemic myelofibrosis
- 26 January 2023
- Published by Elsevier in The Lancet
- Vol. 401 (10373) , 248-249
Gaining MOMENTUM against anaemic myelofibrosis
- Open Access
- 9 December 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-9
Evaluation of a quantitative PCR-based method for chimerism analysis of Japanese donor/recipient pairs
Chimerism analysis is a surrogate indicator of graft rejection or relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Although short tandem repeat PCR (STR-PCR) is the usual method, limited sensitivity and technical variability are matters of concern. Quantitative PCR-based methods to detect single nucleotide polymorphisms (SNP-qPCR) are more sensitive, but their informativity and quantitative accuracy are highly variable. For accurate and sensitive chimerism analysis, a set of KMR kits (GenDx, Utrecht, Netherlands), based on detection of insertions/deletions (indels) by qPCR, have been developed. Here, we investigated informativity and validated the accuracy of KMR kits in Japanese donor/recipient pairs and virtual samples of DNA mixtures representative of Japanese genetic diversity. We found that at least one recipient-specific marker among 39 KMR-kit markers was informative in all of 65 Japanese donor/recipient pairs. Moreover, the percentage of recipient chimerism estimated by KMRtrack correlated well with ratios of mixed DNA in virtual samples and with the percentage of chimerism in HSCT recipients estimated by STR-PCR/in-house SNP-qPCR. Moreover, KMRtrack showed better sensitivity with high specificity when compared to STR-PCR to detect recipient chimerism. Chimerism analysis with KMR kits can be a standardized, sensitive, and highly informative method to evaluate the graft status of HSCT recipients.
- 9 December 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-9
Open AccessEvaluation of a quantitative PCR-based method for chimerism analysis of Japanese donor/recipient pairs
Chimerism analysis is a surrogate indicator of graft rejection or relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Although short tandem repeat PCR (STR-PCR) is the usual method, limited sensitivity and technical variability are matters of concern. Quantitative PCR-based methods to detect single nucleotide polymorphisms (SNP-qPCR) are more sensitive, but their informativity and quantitative accuracy are highly variable. For accurate and sensitive chimerism analysis, a set of KMR kits (GenDx, Utrecht, Netherlands), based on detection of insertions/deletions (indels) by qPCR, have been developed. Here, we investigated informativity and validated the accuracy of KMR kits in Japanese donor/recipient pairs and virtual samples of DNA mixtures representative of Japanese genetic diversity. We found that at least one recipient-specific marker among 39 KMR-kit markers was informative in all of 65 Japanese donor/recipient pairs. Moreover, the percentage of recipient chimerism estimated by KMRtrack correlated well with ratios of mixed DNA in virtual samples and with the percentage of chimerism in HSCT recipients estimated by STR-PCR/in-house SNP-qPCR. Moreover, KMRtrack showed better sensitivity with high specificity when compared to STR-PCR to detect recipient chimerism. Chimerism analysis with KMR kits can be a standardized, sensitive, and highly informative method to evaluate the graft status of HSCT recipients.
- Open Access
- 26 July 2022
- Published by Springer Nature in Research Square
Evaluation of a quantitative PCR-based method for chimerism analysis of Japanese donor/recipient pairs
Chimerism analysis is a surrogate indicator of graft rejection or relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Although short tandem repeat PCR (STR-PCR) is the usual method, limited sensitivity and technical variability are matters of concern. Quantitative PCR-based methods to detect single nucleotide polymorphisms (SNP-qPCR) are more sensitive, but their informativity and quantitative accuracy are highly variable. For accurate and sensitive chimerism analysis, a set of KMR kits (GenDx, Utrecht, Netherlands), based on detection of insertions/deletions (indels) by qPCR, have been developed. Here, we investigated informativity and validated the accuracy of KMR kits in Japanese donor/recipient pairs and virtual samples of DNA mixtures representative of Japanese genetic diversity. We found that at least one recipient-specific marker among 39 KMR-kit markers was informative in all of 65 Japanese donor/recipient pairs. Moreover, the percentage of recipient chimerism estimated by KMRtrack correlated well with ratios of mixed DNA in virtual samples and with the percentage of chimerism in HSCT recipients estimated by STR-PCR/in-house SNP-qPCR. Moreover, KMRtrack showed better sensitivity with high specificity when compared to STR-PCR to detect recipient chimerism. Chimerism analysis with KMR kits can be a standardized, sensitive, and highly informative method to evaluate the graft status of HSCT recipients.
- 26 July 2022
- Published by Springer Nature in Research Square
Open AccessEvaluation of a quantitative PCR-based method for chimerism analysis of Japanese donor/recipient pairs
Chimerism analysis is a surrogate indicator of graft rejection or relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Although short tandem repeat PCR (STR-PCR) is the usual method, limited sensitivity and technical variability are matters of concern. Quantitative PCR-based methods to detect single nucleotide polymorphisms (SNP-qPCR) are more sensitive, but their informativity and quantitative accuracy are highly variable. For accurate and sensitive chimerism analysis, a set of KMR kits (GenDx, Utrecht, Netherlands), based on detection of insertions/deletions (indels) by qPCR, have been developed. Here, we investigated informativity and validated the accuracy of KMR kits in Japanese donor/recipient pairs and virtual samples of DNA mixtures representative of Japanese genetic diversity. We found that at least one recipient-specific marker among 39 KMR-kit markers was informative in all of 65 Japanese donor/recipient pairs. Moreover, the percentage of recipient chimerism estimated by KMRtrack correlated well with ratios of mixed DNA in virtual samples and with the percentage of chimerism in HSCT recipients estimated by STR-PCR/in-house SNP-qPCR. Moreover, KMRtrack showed better sensitivity with high specificity when compared to STR-PCR to detect recipient chimerism. Chimerism analysis with KMR kits can be a standardized, sensitive, and highly informative method to evaluate the graft status of HSCT recipients.